featured
Temozolomide-Based Chemoradiotherapy Regimen for High-Risk Low-Grade Gliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase II Study of a Temozolomide-Based Chemo-Radiotherapy Regimen for High Risk Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group (RTOG) 0424
Int. J. Radiat. Oncol. Biol. Phys 2020 Apr 03;[EPub Ahead of Print], BJ Fisher, SL Pugh, DR Macdonald, A Chakravatri, GJ Lesser, S Fox, CL Rogers, M Werner-Wasik, T Doyle, JP Bahary, JB Fiveash, JA Bovi, SP Howard, HH Michael Yu, D D'Souza, NN Laack, IJ Barani, Y Kwok, DR Wahl, JF Strasser, M Won, MP MehtaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.